Regenxbio (RGNX) EBITDA Margin (2016 - 2025)
Historic EBITDA Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 207.99%.
- Regenxbio's EBITDA Margin rose 313500.0% to 207.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 110.33%, marking a year-over-year increase of 1647600.0%. This contributed to the annual value of 268.11% for FY2024, which is 117100.0% up from last year.
- Latest data reveals that Regenxbio reported EBITDA Margin of 207.99% as of Q3 2025, which was up 313500.0% from 331.75% recorded in Q2 2025.
- In the past 5 years, Regenxbio's EBITDA Margin registered a high of 73.43% during Q4 2021, and its lowest value of 397.71% during Q1 2024.
- Its 5-year average for EBITDA Margin is 238.68%, with a median of 242.03% in 2024.
- In the last 5 years, Regenxbio's EBITDA Margin plummeted by -2555300bps in 2022 and then soared by 4045200bps in 2025.
- Quarter analysis of 5 years shows Regenxbio's EBITDA Margin stood at 73.43% in 2021, then tumbled by -348bps to 182.1% in 2022, then plummeted by -48bps to 269.68% in 2023, then increased by 10bps to 242.03% in 2024, then increased by 14bps to 207.99% in 2025.
- Its EBITDA Margin was 207.99% in Q3 2025, compared to 331.75% in Q2 2025 and 6.81% in Q1 2025.